1,2-Dilinoleoyl-sn-glycero-3-phosphocholine

CAS : 998-06-1

Ref. 3D-FD42822

Informations sur le produit

• Nom: 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine
• Synonymes: (1,2-Dilinoleoyl)-3-lecithin, (2R)-2,3-bis[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl 2-(trimethylammonio)ethyl phosphate, (R-(All-Z))-(4-oxido-10-oxo-7-((1-oxooctadeca-9,12-dienyl)oxy)-3,5,9-trioxa-4-phosphaheptacosa-18,21-dienyl)trimethylammonium 4-oxide, 1,2-Dilinoleoyl-sn-3-glycerophosphorylcholine, 1,2-Dilinoleoyl-sn-glycero-3-phosphatidylcholine, 1,2-Dilinoleoyl-sn-glycerol-3-phosphocholine, 1,2-Dilinoleoylphosphocholine, 1-Linoleoyl-2-linoleoyl-sn-glycero-3-phosphorylcholine, 3,5,9-Trioxa-4-phosphaheptacosa-18,21-dien-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxo-9,12-octadecadienyl)oxy]-, hydroxide, inner salt, 4-oxide, [R-(all-Z)]-, 3,5,9-Trioxa-4-phosphaheptacosa-18,21-dien-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxo-9,12-octadecadienyl)oxy]-, inner salt, 4-oxide, [R-(all-Z)]-, 3,5,9-Trioxa-4-phosphaheptacosa-18,21-dien-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[(9Z,12Z)-1-oxo-9,12-octadecadien-1-yl]oxy]-, inner salt, 4-oxide, (7R,18Z,21Z)-, 3,5,9-Trioxa-4-phosphaheptacosa-18,21-dien-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]oxy]-, inner salt, 4-oxide, (7R,18Z,21Z)-, 49: PN: WO2017201317 SEQID: 122 claimed RNA, <span class="text-smallcaps">L</span>-(+)-α-(α′,β-Dilinoleoyl)-glycerylphosphorylcholine, <span class="text-smallcaps">L</span>-Dilinoleoyllecithin, <span class="text-smallcaps">L</span>-α-Dilinoleoyl phosphatidylcholine, Choline, hydroxide, dihydrogen phosphate, inner salt, ester with 1,2-dilinolein, <span class="text-smallcaps">L</span>-(+)-, DLiPC, Linolein, 1,2-di-, dihydrogen phosphate, monoester with choline hydroxide, inner salt, <span class="text-smallcaps">L</span>-(+)-
• CAS: 998-06-1

Description

1,2-Dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) is a phospholipid that is used in the treatment of insulin resistance and inflammation. DLPC is a stable molecule that exhibits intermolecular hydrogen bonding and has been shown to be effective against inflammatory diseases. DLPC has been used as a liposomal formulation for the treatment of type 2 diabetes by improving insulin sensitivity, which may be due to its ability to inhibit proinflammatory cytokines such as tumor necrosis factor alpha (TNFα). It also binds to the receptor α, which are G protein coupled receptors present on cells involved in inflammatory responses. The binding of DLPC to these receptors leads to increased insulin sensitivity by inhibiting TNFα production.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 782.08 g/mol
• Formule: C₄₄H₈₀NO₈P
• Degré de pureté: Min. 95%